Palit V, Shah T, Biyani C S, Elmasry Y, Sarkar R, Flannigan G M, Puri R
Urology office, Bradford Hospitals NHS Trust, St. Lukes Hospital, Little Horton Lane, Bradford, BD5 0 N A, West Yorkshire, UK.
Int Urol Nephrol. 2005;37(3):507-10. doi: 10.1007/s11255-004-4709-1.
Acute urinary retention (AUR) is one of the commonest causes of admission in urology ward and successful voiding with alpha-blockers has been reported. However, long-term efficacy of Alfuzosin, following an episode of AUR is lacking. This is a continuation of our earlier reported study. We report the results of a 4 year follow-up on patients who were on Alfuzosin SR 5 mg BD, following resumption of voiding after an episode of AUR.
A total of 33 patients voided successfully following AUR in our original study. These patients continued on Alfuzosin SR 5 mg BD and were assessed at 2 and 4 years. Symptomatic assessment was performed with IPSS and QOL symptom score and objective assessment was with urinary flow rate and post void residual volume. Patients who continued to deteriorate symptomatically and objectively or developed further AUR were listed for surgery.
Out of 33 patients, 28 patients were followed up at 2 years (three patients died due to various medical reasons and two did not attend for follow-up). Nineteen patients (68%) underwent transurethral resection of prostate (TURP) for severe lower urinary tract symptom (LUTS) . The mean peak flow rate at 2 years was 8.4 ml/s and the mean residual volume was 112 ml. Ten patients attended for follow up at 4 years. The mean flow rate was 5.17 ml/s and the mean post-void residual volume was 101 ml. Four patients underwent TURP for severe outflow symptoms. At 4 years follow up 24 out of 30 patients (80%) on Alfuzosin needed TURP.
These data do not support the long term use of alpha-blockers in patients who voided successfully after acute urinary retention.
急性尿潴留(AUR)是泌尿外科病房最常见的入院原因之一,已有使用α受体阻滞剂成功排尿的报道。然而,关于阿夫唑嗪在AUR发作后的长期疗效尚缺乏研究。这是我们之前报道研究的延续。我们报告了在AUR发作后排尿恢复后服用阿夫唑嗪缓释片5mg每日两次的患者4年随访结果。
在我们最初的研究中,共有33例患者在AUR后成功排尿。这些患者继续服用阿夫唑嗪缓释片5mg每日两次,并在2年和4年时进行评估。采用国际前列腺症状评分(IPSS)和生活质量症状评分进行症状评估,采用尿流率和排尿后残余尿量进行客观评估。症状和客观指标持续恶化或再次发生AUR的患者被列入手术名单。
33例患者中,28例在2年时接受随访(3例因各种医疗原因死亡,2例未参加随访)。19例患者(68%)因严重下尿路症状(LUTS)接受了经尿道前列腺切除术(TURP)。2年时平均最大尿流率为8.4ml/s,平均残余尿量为112ml。10例患者在4年时接受随访。平均尿流率为5.17ml/s,平均排尿后残余尿量为101ml。4例患者因严重排尿困难症状接受了TURP。在4年随访时,30例服用阿夫唑嗪的患者中有24例(80%)需要接受TURP。
这些数据不支持在急性尿潴留后排尿成功的患者中长期使用α受体阻滞剂。